Home » Topics » Disease categories and therapies » Dermatologic

Dermatologic
RSS

Paramount BioSciences obtains license to SonoLight technology for dermatology indications

May 17, 2007

BF-37 enters phase II study in atopic dermatitis

May 15, 2007

ProCertus BioPharm closes Series A financing

May 14, 2007

P&G terminates Hedgehog agonist hair growth collaboration with Curis

May 11, 2007

CollaGenex discontinues 40 mg cohort in phase II acne study of incyclinide

May 10, 2007

UK-371804: a novel selective urokinase-type plasminogen activator inhibitor from Pfizer

May 8, 2007

New phase II trial for Avugane in acne vulgaris

May 2, 2007

New approvable letter for CIP-Isotretinoin

April 30, 2007

New pediatric eczema study compares EpiCeram to Elidel

April 27, 2007

Alitretinoin shows retreatment benefit in chronic hand eczema

April 26, 2007

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 11, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Italy’s Angelini pays $4.1B cash for rare disease specialist Catalyst
BioWorld
Italian family-owned Angelini Pharma SpA is making its first move into the U.S. market, acquiring rare diseases specialist Catalyst Pharma Inc. in an all-cash...
Circulating sncRNA transcriptome in diabetic kidney disease and SGLT2 inhibitor treatment
BioWorld Science
Small noncoding RNAs (sncRNAs), including miRNAs, piRNAs and snoRNAs, can provide further biological insights into the mechanisms of chronic kidney disease (CKD)...